Peptio

Peptides and metabolic research

The one area of peptide research with large randomised human trials and approved medicines, alongside compounds that have neither.

This is the exception in peptide research. GLP-1 receptor agonists have been through large randomised trials with hard endpoints, and several are approved medicines with published regulatory assessments.

That makes the contrast within this hub stark. Some entries here rest on thousands of trial participants. Others rest on rodent studies. The evidence labels are doing real work.

Peptides studied in this area

  • Retatrutide

    LY3437943, LY-3437943

    Retatrutide is an investigational triple receptor agonist with published phase 3 trials. It is not approved by FDA or EMA, the two regulators checked.

    Human RCTIn clinical trialsweight management

  • Tirzepatide

    LY3298176, Mounjaro, Zepbound

    Tirzepatide is a dual GIP and GLP-1 receptor agonist, approved in the US and the EU for type 2 diabetes and for weight management.

    Human RCTApproved for a medical indicationweight management